Anixa starts subject treatment in Phase I ovarian cancer cell therapy trial

Anixa Biosciences and its partner Moffitt Cancer Center have initiated treatment of the first subject in the Phase I clinical trial of new chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.